Atossa TherapeuticsATOS
About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Employees: 10
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
643% more call options, than puts
Call options by funds: $765K | Put options by funds: $103K
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
13% more funds holding
Funds holding: 67 [Q1] → 76 (+9) [Q2]
4.88% more ownership
Funds ownership: 15.97% [Q1] → 20.85% (+4.88%) [Q2]
14% less capital invested
Capital invested by funds: $36M [Q1] → $31.2M (-$4.86M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Ascendiant Capital Edward Woo 30% 1-year accuracy 14 / 46 met price target | 348%upside $6.50 | Buy Maintained | 11 Sept 2024 |
HC Wainwright & Co. Emily Bodnar 31% 1-year accuracy 34 / 108 met price target | 314%upside $6 | Buy Reiterated | 12 Aug 2024 |
Financial journalist opinion
Based on 3 articles about ATOS published over the past 30 days